HiberCell Acquires Genuity Science in All-Stock Deal
Genuity, which has a $100 million cash position, provides contract genomics and artificial intelligence-driven data sourcing and analytics services for drug development.
Genuity Science, Emory Team on Biomarker Discovery for Neurodegenesis
The bioinformatics and sequencing firm, formerly known as WuXi NextCode, will develop a population clinicogenomic database to support Emory's research.
Genuity Science, Ionis Pharmaceuticals Partner on Antisense Therapy Development
Genuity Science, formerly known as WuXi NextCode, will receive a combination of upfront, development milestone, and product royalty payments under the deal.
Genuity Science Gains Access to BioVU With Nashville Biosciences Deal
Genuity, formerly known as WuXi NextCode, will sequence, analyze, and harmonize samples from Vanderbilt's biobank to inform biomarker and drug discovery.
Based in Boston with operations in Ireland and Iceland, the reorganized company is supporting COVID-19 testing and population genomics as it sheds its China division.